{
  "extraction_metadata": {
    "timestamp": "2025-10-01T13:26:01.884607",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, response (CR, PR, mRECIST), tumour recurrence, intraoperative complications, mortality, morbidity, disease progression, partial response, time to deterioration, time to progression of the tumor, adverse events, neurotoxicity, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, SF-36, visual analogue scale",
      "ChunksUsed": 20,
      "ContextTokens": 4698
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, portal vein thrombosis, recurrence, adverse events (general)",
      "ChunksUsed": 20,
      "ContextTokens": 4689
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, response rates (mRECIST), intraoperative complications, mortality, morbidity, disease progression, time to deterioration, time to progression of the tumor, recurrence risk, adverse events, neurotoxicity, quality of life, EORTC QLQ-C30, EQ-5D-5L, SF-36, visual analogue scale",
      "ChunksUsed": 20,
      "ContextTokens": 4698
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, complications, long-term survival, 5-year survival, risk of recurrence, local tumour control, quality of life",
      "ChunksUsed": 20,
      "ContextTokens": 3097
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, prognosis (BCLC staging system), adverse events, long-term treatment-related complications",
      "ChunksUsed": 20,
      "ContextTokens": 4528
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "bleeding, tumour seeding, side-effects (general)",
      "ChunksUsed": 11,
      "ContextTokens": 2774
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival, progression-free survival, time-to-progression, objective response rate (modified RECIST criteria), response rates (RECIST criteria), adverse events, diarrhoea, fatigue, nausea, neutropenia, anaemia, headache, rash, liver and biliary damages, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, SF-36, visual analogue scale",
      "ChunksUsed": 20,
      "ContextTokens": 5940
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "improved survival, progression-free survival, recurrence rate, disease progression, mortality not related to hepatocellular carcinoma, adverse events, marked impairment of hepatic function, increased carcinogenicity, objective responses, Child-Pugh score, Milan criteria, overall survival",
      "ChunksUsed": 20,
      "ContextTokens": 4764
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, adverse events, adverse events (Grade â‰¥ 3), quality of life, overall survivability, tumour response rate, complications, local tumour control, success rate (downstaging/bridging), early detection of recurrence, early detection of de novo tumor, pulmonary metastasis, lung metastasis, distress, physical complaints, psychological complaints, psychosocial problems, general complaints, Functional Assessment of Cancer Therapy (FACT-G), FACT-Hepatobiliary (FACT-Hep), EQ-5D, EQ-VAS",
      "ChunksUsed": 20,
      "ContextTokens": 4673
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "progression-free survival, overall survival, response rates (RECIST criteria), response rates (mRECIST), response rates (RECIS systems), perioperative mortality, adverse events (general), time to progression, completeness of ablation (multiphase computed tomography with contrast), completeness of ablation (magnetic resonance imaging with contrast), effectiveness of ablation (magnetic resonance imaging), effectiveness of ablation (multiphase computed tomography), effectiveness of ablation (ultrasonography not appropriate), disease progression, bridging therapy success, detection of atypical hepatocellular radiological features (contrast radiology), diagnosis based on non-invasive radiological criteria, diagnosis based on pathomorphological evaluation, diagnosis based on histopathological examinations, diagnosis based on ultrasound screening, diagnosis based on multiphasic computed tomography, diagnosis based on magnetic resonance imaging, diagnosis based on biopsy, diagnosis based on vascular enhancement (wash-in), diagnosis based on wash-out, diagnosis based on pathomorphological report, diagnosis based on immunohistochemical confirmation, diagnosis based on genetic diagnosis, diagnosis based on immuno-historical markers, diagnosis based on HSP70, diagnosis based on glypican GS-3, diagnosis based on non-cellular tissue material, diagnosis based on patomorphological report content, diagnosis based on contrast imaging (4-phase computed tomography or dynamic magnetic resonance imaging), diagnosis based on ultrasound surveillance, diagnosis based on follow-up ultrasound examinations, diagnosis based on repeat biopsy, diagnosis based on observation of non-compatibility between histopathological and ultrasound examinations, diagnosis based on high quality contrast imaging, diagnosis based on clinical evaluation, diagnosis based on prospective mRECIST test results",
      "ChunksUsed": 15,
      "ContextTokens": 3401
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "survival, quality of life, EORTC QLQ-C30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, response rate (RECIST criteria), response rate (mRECIST criteria), tumour viability (mRECIST criteria), nutritional status, decompensation (varicose vein bleeding), decompensation (clinically detectable ascites), decompensation (hepatic encephalopathy, grade > 1 on the New Haven criteria)",
      "ChunksUsed": 20,
      "ContextTokens": 3362
    }
  }
}